CD163 and neoplasm: DRS measurements were correlated to end-point immunohistochemistry (IHC) markers of hypoxia (carbonic anhydrase-9) and microvasculature (CD31), along with tumor-associated macrophage recruitment (CD68) and M2 tumor-associated macrophage recruitment (CD163).